Related Experiment Video
Updated: Apr 8, 2026

Assessment of Vascular Function in Patients With Chronic Kidney Disease
Published on: June 16, 2014
Time-dependent risk factors associated with the decline of estimated GFR in CKD patients
Wen-xiu Chang1,2, Shigeyuki Arai1, Yoshifuru Tamura1
1Department of Internal Medicine, Teikyo University School of Medicine, 2-11-1 Kaga, Itabashi, Tokyo, 173-8605, Japan.
Insights
Time-averaged analysis reveals key risk factors for chronic kidney disease (CKD) progression. Hyperphosphatemia, proteinuria, and anemia are strongly linked to rapid decline in estimated glomerular filtration rate (eGFR).
Area of Science:
- Nephrology
- Clinical Epidemiology
Background:
- Chronic kidney disease (CKD) progression is influenced by modifiable risk factors.
- Analyzing risk factors using follow-up parameters is crucial for effective management.
- Understanding time-dependent risk factors can help halt CKD progression.
Purpose of the Study:
- To examine time-dependent risk factors for CKD progression using time-averaged values.
- To identify characteristics of patients experiencing rapid CKD progression.
Main Methods:
- Retrospective cohort study of 770 patients with CKD stage 3-4.
- Calculation of time-dependent parameters using time-averaged values.
- Classification of estimated glomerular filtration rate (eGFR) decline into stable, moderate, and rapid progression groups.
- Multivariate regression analyses on baseline and time-averaged datasets.
Main Results:
- eGFR decline was significantly higher in males than females.
- % decline of eGFR was associated with male sex, proteinuria, phosphorus, and systolic blood pressure.
- Rapid CKD progression was linked to proteinuria, phosphorus, albumin, and hemoglobin in follow-up data.
Conclusions:
- Time-averaged values offer valuable clinical insights for targeting risk factors in CKD.
- Hyperphosphatemia, proteinuria, and anemia are critical targets for intervention in CKD management.
- Early intervention for these factors may slow the progression of chronic kidney disease.
Background:
Targeting the modifiable risk factors may help halt the progression of CKD, thus risk factor analysis is better performed using the parameters in the follow-up. This study aimed to examine the time-dependent risk factors for CKD progression using time-averaged values and to investigate the characteristics of rapid progression group.
Methods:
This is a retrospective cohort study enrolling 770 patients of CKD stage 3-4. Time-dependent parameters were calculated as time-averaged values by a trapezoidal rule. % decline of estimated GFR (eGFR) per year from entry was divided to three groups: <10% (stable), 10-25% (moderate progression), and ≥25% (rapid progression). Multivariate regression analyses were employed for the baseline and the time-averaged datasets.
Results:
eGFR decline was 2.83 ± 4.04 mL/min/1.73 m(2)/year (8.8 ± 12.9 %) in male and 1.66 ± 3.23 mL/min/1.73 m(2)/year (5.4 ± 11.0%) in female (p < 0.001). % decline of eGFR was associated with male, proteinuria, phosphorus, and systolic blood pressure as risk factors and with age, albumin, and hemoglobin as protective factors using either dataset. Baseline eGFR and diabetic nephropathy appeared in the baseline dataset, while uric acid appeared in the time-averaged dataset. The rapid progression group was associated with proteinuria, phosphorus, albumin, and hemoglobin in the follow-up.
Conclusion:
These results suggest that time-averaged values provide insightful clinical guide in targeting the risk factors. Rapid decline of eGFR is strongly associated with hyperphosphatemia, proteinuria, and anemia indicating that these risk factors should be intervened in the follow-up of CKD.
Related Concept Videos
Drug Dosing in Renal Diseases: Estimation of Glomerular Filtration Rate Based on Serum Creatinine Concentration
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion
Drug Dosing in Renal Diseases: Measurement of Glomerular Filtration Rate
Acute Kidney Injury III: Clinical Manifestations
Drug Dosing in Renal Diseases: Dose Adjustments Based on Drug Clearance and Elimination Rate Constant
Chronic Kidney Disease I: Introduction

